Capio announces the proposed sale of Capio France to Vivalto Santé
Capio has entered into exclusivity regarding the proposed sale of Capio France to Vivalto Santé (“Vivalto”) pending the finalization of the documentation related thereto as is customary in the French market. The consideration for the proposed transaction would be an upfront enterprise value of MEUR 425 plus an earn-out contingent on 2018 financial performance, up to a total enterprise value of MEUR 455. The completion of the transaction would be subject to certain conditions, including the approval of Capio’s shareholders at an EGM, as required under Swedish takeover regulation, to be convened in due course.
Capio AB (publ) is a leading, pan- European healthcare provider operating in five countries (Sweden, Norway, Denmark, France and Germany) and provided in 2017 over 5 million patient visits across the Group’s facilities.
Capio was advised by Mannheimer Swartling in the proposed transaction together with Allen & Overy in Paris.
